-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmuneOnco FY26 interim revenue falls 33.2% to RMB 25.4 million; R&D expenses drop 7.9% to RMB 154.8 million

PUBT·08/26/2026 13:41:57
Listen to the news
ImmuneOnco FY26 interim revenue falls 33.2% to RMB 25.4 million; R&D expenses drop 7.9% to RMB 154.8 million
  • ImmuneOnco posted revenue of RMB 25.4 million for the six months ended June 30, 2026, down 33.2%.
  • Research and development expenses fell 7.9% to RMB 154.8 million.
  • Collaboration-development revenue totaled RMB 25.25 million, down from payments tied to the 2024 Axion Bio licensing deal.
  • IMM01 Phase III CMML study completed enrollment of 173 patients; data cut-off expected at end-2026 with interim analysis planned.
  • IMM0306 entered Phase III in relapsed/refractory follicular lymphoma; Phase II SLE trial began enrolling with 90 patients targeted.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12301169), on August 26, 2026, and is solely responsible for the information contained therein.